Bailard, Inc. 89bio, Inc. Transaction History
Bailard, Inc.
- $3.84 Billion
- Q4 2024
Shares
3 transactions
Others Institutions Holding ETNB
# of Institutions
167Shares Held
109MCall Options Held
73.6KPut Options Held
1.19M-
Janus Henderson Group PLC London, X015.2MShares$173 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$162 Million1.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.99MShares$91.4 Million2.33% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$84.4 Million0.87% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$80.3 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $532M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...